Imagion Biosystems

Imagion Biosystems Debt

The Debt of Imagion Biosystems (IBX.AX) as of Nov 11, 2026 is 2.56 M AUD. In the previous year, Debt was 2.85 M AUD — a change of -9.94% (lower).

Debt

2.56 MAUD

YoY

-9.94%

Last updated:

In 2025, Imagion Biosystems's total debt was 2.56 M AUD, a -9.94% change from the 2.85 M AUD total debt recorded in the previous year.

The Imagion Biosystems Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
54,516.00 AUD
Jan 1, 2019
876,780.00 AUD
Jan 1, 2020
660,980.00 AUD
Jan 1, 2021
46,021.00 AUD
Jan 1, 2022
4.60 M AUD
Jan 1, 2023
6.04 M AUD
Jan 1, 2024
2.85 M AUD
Jan 1, 2025
2.56 M AUD
The Imagion Biosystems Debt history
YEARDebtYoY
2.56 MAUD-9.94%
2.85 MAUD-52.85%
6.04 MAUD+31.14%
4.60 MAUD+9,904.93%
46,021.00AUD-93.04%
660,980.00AUD-24.61%
876,780.00AUD+1,508.30%
54,516.00AUD-31.87%
80,014.00AUD-99.43%
13.93 MAUD+46.70%
9.49 MAUD+126.63%
4.19 MAUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Imagion Biosystems Stock analysis

What does Imagion Biosystems do? Imagion Biosystems Ltd develops non-radioactive diagnostic imaging technology through its MagSense and PrecisionMRX product lines. MagSense uses cancer-specific magnetic nanoparticles for detecting breast, prostate, and ovarian cancers, with a Phase I clinical study ongoing for its HER2 imaging agent. PrecisionMRX offers coated nanoparticles including Dextran-Coated, mPEG Coated, Oleic Acid Coated, and Carboxylic Acid Functionalized variants for magnetic relaxometry applications. The company generates revenue primarily through research and development activities, focusing on advanced cancer diagnostics and medical imaging solutions. The firm operates exclusively in the Research and Development segment, targeting medical professionals and healthcare institutions requiring innovative diagnostic tools. MagSense technology is designed as an injectable solution tailored to specific cancer types, while PrecisionMRX nanoparticles serve biomedical applications demanding high precision. These products are developed for use in cancer diagnostics, with clinical studies validating their effectiveness in detecting critical diseases. Imagion Biosystems' revenue streams derive from the development and commercialization of its proprietary imaging technologies. The company's MagSense platform enables functional imaging for cancer detection without radioactive materials, appealing to healthcare providers seeking safer diagnostic alternatives. PrecisionMRX nanoparticles support specialized biomedical applications, offering customizable solutions for medical imaging needs across various cancer types. Imagion Biosystems is one of the most popular companies on Eulerpool.

Debt Details

Understanding Imagion Biosystems's Debt Structure

Imagion Biosystems's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Imagion Biosystems's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Imagion Biosystems’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Imagion Biosystems’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Imagion Biosystems stock

Debt of Imagion Biosystems is 2.56 M AUD in 2025.

Debt of Imagion Biosystems changed from 2.85 M AUD to 2.56 M AUD, representing a -9.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Imagion Biosystems since 2006 – with annual values, charts, and detailed analysis.

Debt's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Imagion Biosystems historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Imagion Biosystems

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Imagion Biosystems